EcoDrugPlus

Estrogen-Related Receptor Gamma A

Ensembl ID : ENSGACG00000016275
Gene Symbol: ESRRGA
1 Cross references
203 Possible Orthologues:

Exportin 1

Ensembl ID : ENSGACG00000002743
Gene Symbol: XPO1
1 Cross references
217 Possible Orthologues:

Exportin 1

Ensembl ID : ENSGACG00000019736
Gene Symbol: XPO1
1 Cross references
229 Possible Orthologues:

Farnesyl Diphosphate Synthase (Farnesyl Pyrophosphate Synthetase, Dimethylallyltranstransferase, Geranyltranstransferase)

Ensembl ID : ENSGACG00000011874
Gene Symbol: FDPS
1 Cross references
269 Possible Orthologues:

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSGACG00000010266
Gene Symbol: FDFT1
1 Cross references
221 Possible Orthologues:

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSGACG00000018695
Gene Symbol: FNTA
1 Cross references
222 Possible Orthologues:

Farnesyltransferase, Caax Box, Beta

Ensembl ID : ENSGACG00000007742
Gene Symbol: FNTB
1 Cross references
203 Possible Orthologues:

Fibroblast Growth Factor Receptor 1

Ensembl ID : ENSGACG00000015518
Gene Symbol: FGFR1
1 Cross references
201 Possible Orthologues:

Fibroblast Growth Factor Receptor 1a

Ensembl ID : ENSGACG00000012410
Gene Symbol: FGFR1A
2 Cross references
208 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSGACG00000003443
Gene Symbol: FGFR2
1 Cross references
221 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSGACG00000004533
Gene Symbol: FGFR3
1 Cross references
191 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSGACG00000003066
Gene Symbol: FLT1
1 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).